Reuters logo
BRIEF-Nordic Nanovector provides results from phase 1/2 study of Betalutinwill
November 1, 2017 / 1:33 PM / 22 days ago

BRIEF-Nordic Nanovector provides results from phase 1/2 study of Betalutinwill

Nov 1 (Reuters) - NORDIC NANOVECTOR ASA

* RESULTS FROM LYMRIT 37-01 PHASE 1/2 STUDY OF BETALUTINWILL BE PRESENTED IN A POSTER AT 59TH ANNUAL ASH MEETING​

* ‍NO UNEXPECTED SAFETY FINDINGS, SAFETY PROFILE IS BOTH PREDICTABLE AND MANAGEABLE​

* SAYS ‍SINGLE-AGENT BETALUTIN IS HIGHLY ACTIVE AND WELL TOLERATED IN RECURRENT INHL​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below